Is Phaarmasia a good stock to invest in?

Phaarmasia can be analyzed on the following key metrics - TTM P/E: - Sector P/E: 22.67 Dividend Yield: 0% D/E ratio: -

Phaarmasia Share Price

Sector: Biotechnology & Drugs

Powered by

33.93 -0.01 (-0.03%)

1D
5D
1M
3M
6M
1Y
5Y
MAX

Price Range

Today’s Low 32.50

Today’s High 33.93

52 Week Low 23.60

52 Week High 64.75

Key Metrics

Market Cap (In Cr) 23.16
Beta 1.91
Div. Yield (%) 0
P/B -
TTM P/E -
Peg Ratio -
Sector P/E 22.67
D/E 0
Open Price 33.75
Prev Close 33.94

View All Metrics

Phaarmasia Analysis

Price Analysis

1 Week

-0.18%
3 Months

13.51%
6 Month

-37.61%
YTD

-30.02%
1 Year

-39.24%

Risk Meter

47% Low risk
47% Moderate risk
47% Balanced Risk
47% High risk
47% Extreme risk

Phaarmasia Financials

INCOME
BALANCE SHEET
Cashflow

DATE

Annual

Quarterly

Period
2025

Total Revenue
24.37

Selling/ General/ Admin Expenses Total
1.91

Depreciation/ Amortization
0.32

Other Operating Expenses Total
5.01

Total Operating Expense
26.7

Operating Income
-2.33

Net Income Before Taxes
-1.6

Net Income
-1.59

Diluted Normalized EPS
-2.33

Period
2024

Total Revenue
30.59

Selling/ General/ Admin Expenses Total
1.76

Depreciation/ Amortization
0.34

Other Operating Expenses Total
5.05

Total Operating Expense
31.76

Operating Income
-1.16

Net Income Before Taxes
-0.55

Net Income
-0.52

Diluted Normalized EPS
-0.76

Period
2023

Total Revenue
27.49

Selling/ General/ Admin Expenses Total
1.64

Depreciation/ Amortization
0.36

Other Operating Expenses Total
4.94

Total Operating Expense
29.39

Operating Income
-1.9

Net Income Before Taxes
-1.43

Net Income
-1.26

Diluted Normalized EPS
-1.84

Period
2022

Total Revenue
17.22

Selling/ General/ Admin Expenses Total
1.38

Depreciation/ Amortization
0.29

Other Operating Expenses Total
3.71

Total Operating Expense
19.24

Operating Income
-2.03

Net Income Before Taxes
-1.56

Net Income
-1.55

Diluted Normalized EPS
-2.27

Period
2021

Total Revenue
19.9

Selling/ General/ Admin Expenses Total
1.5

Depreciation/ Amortization
0.34

Other Operating Expenses Total
3.88

Total Operating Expense
20.3

Operating Income
-0.4

Net Income Before Taxes
0.48

Net Income
0.31

Diluted Normalized EPS
0.46

Period
2020

Total Revenue
24.45

Selling/ General/ Admin Expenses Total
1.58

Depreciation/ Amortization
0.4

Other Operating Expenses Total
4.26

Total Operating Expense
24.03

Operating Income
0.42

Net Income Before Taxes
0.96

Net Income
0.54

Diluted Normalized EPS
0.79

Period
2019

Total Revenue
25.65

Selling/ General/ Admin Expenses Total
1.73

Depreciation/ Amortization
0.46

Other Operating Expenses Total
6.99

Total Operating Expense
25.39

Operating Income
0.26

Net Income Before Taxes
0.83

Net Income
0.78

Diluted Normalized EPS
1.14

View detailed financials

Forecast

Income Sheet (In Cr) Net Income Vs Revenue

Returns Metrics (In Cr) ROA Vs ROE

Forecast

Balance Sheet Asset vs Liability

Forecast

Cash Flow Operating vs Investing

Phaarmasia Technical

Moving Average SMA

5 Day32.92
10 Day32.62
20 Day30.32

50 Day29.82
100 Day33.41
300 Day42.36

Phaarmasia Peers

Price
Ratio

Name
Latest Price
Change
% Change
52W High
52W Low
Mkt. Cap

Ishita Drugs And Industries
82.15
-1.85
-2.2
104.75
62.35
24.57

Zenith Health Care
4.4
0
0
6.87
3.82
23.65

Phaarmasia
33.93
-0.01
-0.03
64.75
23.6
23.16

Bacil Pharma
37.68
0
0
62.56
14.85
22.19

Norris Medicines
19
0.16
0.85
27.74
11.52
19

Phaarmasia Shareholding

Shareholding Pattern

Shareholding Trend

Shareholding(%) v/s Date

View All

Corporate Actions

Board Meeting
AGM
Dividends
Bonus
Split
Rights

Meeting Date
Purpose

28-May-25
Audited Results

14-Feb-25
Quarterly Results

05-Nov-24
Quarterly Results

12-Aug-24
Quarterly Results

25-May-24
Audited Results

13-Feb-24
Quarterly Results

14-Nov-23
Quarterly Results

14-Aug-23
Quarterly Results

25-May-23
Audited Results

13-Feb-23
Quarterly Results

Meeting Date
Announced on
Purpose

10-Jul-23
19-Jun-23
AGM

27-Sept-22
12-Aug-22
AGM

23-Sept-21
06-Aug-21
AGM

View All

Company Profile

ABOUT Phaarmasia

Industry Biotechnology & Drugs
ISIN INE486I01016
BSE Code 523620

Phaarmasia Limited is an India-based company, which is primarily engaged in the manufacturing and sale of oral contraceptive pills (OCPs). The Company manufactures and markets oral contraceptive tablets with various therapeutic dosage combinations along with iron tablets for the Ministry of Health & Family Welfare and for exports. Its product categories include Hormone Products and Herbal Products. Its hormone products include Estradiol Valerate Tablets; Medroxyprogesterone Acetate Tablets; Cabergoline Tablets; Clomiphene Citrate Tablets; Levonorgestrel Tablet; Fluoxymesterone tablets; Liothyronine Sodium tablets; Oxandrolone tablets and others. Its herbal products include Smyle Herbal Toothpaste; Smyle Cough & Sore Throat Reliver and Smyle Mouth Ulcer Gel. Its injectables include Testosterone Cypionate Injection; Methenolone Enanthate Injection; Drostanolone, Testosterone and Trenbolone Inj, and Stanozolol Cypionate Inj.

MANAGEMENT

Eswara Rao Nagineni Chief Financial Officer
Urvashi Bhatia Chief Compliance Officer, Company Secretary
Maneesh Sapte Managing Director
Yallapragada Bhaskara Rao Whole-Time Director

PHAARMASIA SUMMARY

Phaarmasia is trading 0.03% lower at Rs 33.93 as compared to its last closing price. Phaarmasia has been trading in the price range of 33.93 & 32.50. Phaarmasia has given -30.02% in this year & -0.18% in the last 5 days.

The company posted a net profit of -0.53 Crores in its last quarter.

Listed peers of Phaarmasia include Ishita Drugs And Industries (-2.2%), Zenith Health Care (0%), Phaarmasia (-0.03%) etc.

Phaarmasia has a 73.51% promoter holding & 26.49% public holding.

FAQs about Phaarmasia

Phaarmasia is trading at 33.93 as on 27 Jun, 2025 3:06:05 PM. This is -0.03% lower as compared to its previous closing price of 33.94

The market capitalization of Phaarmasia is 23.16 Cr as on 27 Jun, 2025 3:06:05 PM.

The 52 wk high for Phaarmasia is 64.75 whereas the 52 wk low is 23.60

Phaarmasia can be analyzed on the following key metrics -

TTM P/E: -
Sector P/E: 22.67
Dividend Yield: 0%
D/E ratio: -

Phaarmasia reported a net profit of -1.59 Cr in 2025.

Phaarmasia Quick Links

Equity Quick Links

Top Gainers | Top Losers | Indian Indices | BSE Active Stocks | NSE Active Stocks

Phaarmasia Share Price

Price Range

Key Metrics

Phaarmasia Analysis

Phaarmasia Financials

Forecast

Forecast

Forecast

Phaarmasia Technical

Phaarmasia Peers

Phaarmasia Shareholding

Shareholding Pattern

Shareholding Trend

Corporate Actions

Company Profile

ABOUT Phaarmasia

MANAGEMENT

PHAARMASIA SUMMARY

FAQs about Phaarmasia

Wait for it…

Wait for it…

Congratulations!

Subscribe to continue